Early Phase

SGS' Life Science Services, part of the SGS group (53.000 employees) has 30 years of experience as a global contract service organization providing integrated solutions from preclinical activities to Phase I-IV trials, bioanalytical and QC testing. With more than 1,300 employees and 2,000 clinical trials performed, SGS serves the pharmaceutical, biotechnology and medical device industries throughout Europe, North America and Asia. Through years of executing complex clinical trials, SGS began the European early phase trials benchmark CRO to early phase studies.

SGS offers competitive advantages for your clinical development:

• Over 30 years experience in scientific input to build up innovative and customized study design
• Only 2-4 weeks study initiation timelines in Belgium & France, respectively
• Strong expertise in Combined Protocols offering time savings from FIH to POC
• Comprehensive background in QT/QTc trials: 6 per year
• Capabilities to conduct C14-based ADME studies
• Easy access to patients and special populations
• Large state-of-the-art clinical units with over 160 beds in total enabling study flexibility
• Full regulatory and medical affairs support

Early demonstration of a drug candidate's relevance provides key information on how or whether to move forward in development. Critical time points for collecting this information often lie in the pre-IND stage of development and at the early Proof of Concept stage.

• Microdosing SGS' clinical facilities are fully authorized for 14C to conduct AMS microdosing trials with a GMP pharmacy accreditation. In addition for PET microdosing studies, specialized contracted laboratory facilities have a cyclotron for the production of the radionuclide and are certified for radionuclide labelled drug synthesis.
• Proof of Mechanism/Concept Through working many years in the field of early compound development, SGS has gained a unique expertise in clinical trials at low pharmacologically active dose and Early Proof-of-Concept trials, e.g.: Asthma challenges (exercise, metacholin, allergen); Brain receptor occupancy (PET); Cardiac telemetry; Coagulation-thrombolysis tests; CSF sampling. A complete list is available on the SGS web site.